Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1 AUD | +4.17% | -4.76% | -9.09% |
May. 09 | Transcript : PYC Therapeutics Limited, Q2 2024 Earnings Call, May 09, 2024 | |
Apr. 22 | Australian Shares Rebound Amid Easing Middle East Tensions, Ahead of Local Inflation Data | MT |
Sales 2024 * | 8M 5.28M | Sales 2025 * | 8M 5.28M | Capitalization | 467M 308M |
---|---|---|---|---|---|
Net income 2024 * | -31M -20.46M | Net income 2025 * | -34M -22.44M | EV / Sales 2024 * | 48.9 x |
Net cash position 2024 * | 75.22M 49.65M | Net cash position 2025 * | 96.04M 63.39M | EV / Sales 2025 * | 46.3 x |
P/E ratio 2024 * |
-13.7
x | P/E ratio 2025 * |
-13.7
x | Employees | 5 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.29% |
Latest transcript on PYC Therapeutics Limited
1 day | +4.17% | ||
1 week | -4.76% | ||
Current month | +3.09% | ||
1 month | +8.70% | ||
3 months | +23.46% | ||
6 months | +51.52% | ||
Current year | -9.09% |
Managers | Title | Age | Since |
---|---|---|---|
Rohan Hockings
CEO | Chief Executive Officer | 40 | - |
Andrew Taylor
DFI | Director of Finance/CFO | - | - |
Kevin Hart
DFI | Director of Finance/CFO | 62 | 17-07-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 76 | 21-03-16 | |
Jason Haddock
BRD | Director/Board Member | 54 | 21-03-28 |
Alan W. Tribe
CHM | Chairman | 76 | 18-04-10 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 0.1 | +4.17% | 977,647 |
24-05-09 | 0.096 | -4.00% | 1,928,464 |
24-05-08 | 0.1 | -9.09% | 3,017,633 |
24-05-07 | 0.11 | 0.00% | 2,048,046 |
24-05-06 | 0.11 | +4.76% | 7,002,112 |
Delayed Quote Australian S.E., May 10, 2024 at 02:10 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-9.09% | 308M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- PYC Stock